In:
Blood, American Society of Hematology, Vol. 122, No. 4 ( 2013-07-25), p. 515-522
Kurzfassung:
Approximately 40% of patients with undetectable minimal residual disease on imatinib can stop treatment without loss of molecular response. Patients in treatment-free remission still have detectable BCR-ABL DNA several years after stopping imatinib.
Materialart:
Online-Ressource
ISSN:
0006-4971
,
1528-0020
DOI:
10.1182/blood-2013-02-483750
Sprache:
Englisch
Verlag:
American Society of Hematology
Publikationsdatum:
2013
ZDB Id:
1468538-3
ZDB Id:
80069-7